Target protein: EIF2AK2 (Uniprot ID: P19525), also known as PKR, is a serine/threonine kinase activated by double-stranded RNA during viral infections. It phosphorylates EIF2S1 to inhibit protein synthesis and regulate apoptosis .
Conjugate: Biotin enables streptavidin-HRP binding in assays like ELISA and Western blot (WB) .
Immunogen: Epitopes vary by product, including regions such as AA 251-360/551 or AA 329-551 .
Host species: Primarily rabbit (polyclonal) or mouse (monoclonal) .
The biotin conjugate enhances detection sensitivity in multiple techniques:
Viral response studies: EIF2AK2 antibodies confirmed upregulated kinase activity during influenza A infection in murine models .
Apoptosis regulation: Phospho-specific antibodies (e.g., anti-T446) validated EIF2AK2’s role in stress-induced cell death .
Tissue specificity: High expression observed in hematopoietic tissues (spleen, thymus) compared to non-hematopoietic organs .
Specificity: Verified via siRNA knockdown and peptide blocking in WB .
Cross-reactivity: No significant reactivity with non-human primate or avian orthologs reported .
Lot consistency: Suppliers provide batch-specific data sheets ensuring reproducibility .
Specificity validation requires a multi-step approach. First, compare antibody reactivity against recombinant EIF2AK2 fragments (e.g., AA 329-551) and full-length protein lysates from cell lines with known EIF2AK2 expression (e.g., HeLa, 293T) . Include knockout controls, such as CRISPR-edited EIF2AK2-null cells, to confirm the absence of off-target binding. For the biotin conjugate, pre-block membranes with streptavidin to neutralize endogenous biotin signals. A 69 kDa band should dominate in human lysates, as observed in Bosterbio’s validation . Cross-reactivity assessments across species (e.g., mouse, rat) are critical, as some antibodies exhibit restricted reactivity .
Optimal IHC requires antigen retrieval using citrate buffer (pH 6.0) and a primary antibody dilution of 1:100–1:500, depending on tissue fixation methods. For biotin-conjugated antibodies, amplify signals using streptavidin-HRP complexes and DAB chromogens. Prioritize tissues with high EIF2AK2 expression (e.g., thymus, spleen) for positive controls. Include isotype-matched irrelevant antibodies to distinguish nonspecific binding.
Biotin-conjugated EIF2AK2 antibodies stored at -80°C retain activity for >2 years, while repeated freeze-thaw cycles >3× reduce binding capacity by 40% . Storage buffers containing 50% glycerol and 0.03% Proclin 300 prevent aggregation . For long-term studies, aliquot antibodies into single-use volumes to minimize degradation.
In viral infection models, pair biotinylated EIF2AK2 antibodies with fluorescent streptavidin probes (e.g., Alexa Fluor 647) and co-stain with markers of viral replication (e.g., dsRNA). Use spectral flow cytometry to resolve EIF2AK2 activation kinetics in CD14+ monocytes versus T cells. Critical controls include:
Unconjugated competition: Pre-incubate antibodies with recombinant EIF2AK2 (90–358 AA) to block binding.
Stress induction: Treat cells with poly(I:C) to activate PKR pathways , ensuring antibody specificity correlates with phosphorylated EIF2AK2 levels.
The PMC study identified conflicting variant effects: some increase kinase activity (gain-of-function), while others reduce it (loss-of-function) . To reconcile this:
Functional complementation: Express wild-type and mutant EIF2AK2 in PKR-deficient cells and measure interferon-β production via ELISA.
Phosphorylation profiling: Use phospho-specific antibodies (e.g., anti-pThr446) alongside biotin conjugates to quantify activation states.
Stress assays: Expose variants to oxidative stress (H2O2) or viral mimics; gain-of-function mutants will hyperactivate stress granule formation.
EIF2AK2 regulates both apoptosis (via eIF2α phosphorylation) and autophagy (mTOR suppression). In iPSC-derived neurons with DYT33-associated mutations , monitor these pathways using:
Time-course Western blots: Track phospho-eIF2α (Ser51) and LC3-II/LC3-I ratios alongside total EIF2AK2 levels .
Subcellular fractionation: Isolate nuclear and cytoplasmic fractions to determine if mutants mislocalize (e.g., cytoplasmic aggregation) .
This duality arises from context-dependent roles:
Pro-survival: In glioblastoma, EIF2AK2 stabilizes HIF-1α under hypoxia .
Pro-apoptotic: In colorectal cancer, PKR activation promotes caspase-3 cleavage .
Solution: Contextualize findings using pathway enrichment analysis (e.g., KEGG’s viral carcinogenesis pathway) and condition-specific knockdown models.
Enhance epitope accessibility: Use gentle fixation (4% PFA, 10 min) and permeabilization (0.1% Triton X-100).
Signal amplification: Employ biotin-tyramide deposition (TSA kits) for low-abundance targets .
Validate with ELISA: Compare flow cytometry mean fluorescence intensity (MFI) with ELISA OD450 readings (R² >0.9 confirms linearity) .